Viibryd Acute Pancreatitis (Pancreatic Cancer)

A recent communication from the U.S. Food & Drug Administration (FDA) suggests Viibryd may be associated with reports of acute pancreatitis. In addition to being life-threatening, the condition is also considered a risk factor for pancreatic cancer.

Viibryd Lawsuit Reviews

The attorneys at Bernstein Liebhard LLP are investigating potential Viibryd lawsuits involving acute pancreatitis and pancreatic cancer. If you or a loved one took Viibryd and were diagnosed with either of these conditions, please call (888) 994-5118 to discuss your experience with a member of our legal team.

FDA Seeks Viibryd Label Change

Viibryd is an antidepressant medication approved in 2011 to treat adults with major depressive disorder, or MMD. It was and remains the only drug of its kind – a Selective Serotonin Reuptake Inhibitor (SSRI) and 5HT1a receptor partial agonist. By 2014, Viibryd was the third most prescribed antidepressant, surpassed only by Cymbalta and Prestiq.

A letter issued by the FDA  to the manufacturer of Viibryd in 2016 indicated that the agency was seeking changes to the drug’s label regarding reports of acute pancreatitis. The modifications would be made to the label’s Post-marketing Experience section, which indicates that acute pancreatitis has been reported in Viibryd patients since the drug first came on the market.

What is Acute Pancreatitis?

Acute pancreatitis is an inflammation of the pancreas that proves fatal around 10% of the time. The condition is marked by the gradual or sudden onset of pain in the upper abdomen that sometimes extends to the back. The pain may start out mild, and become worse upon eating.  Other possible symptoms include:

  • Swollen and tender abdomen
  • Nausea and vomiting
  • Fever
  • Rapid pulse

According to the National Pancreas Foundation, acute pancreatitis results in 300,000 U.S. hospital admissions every year. In most cases, patients are hospitalized for 3-5 days in order to receive pain medication and intravenous fluids. The cost to the U.S. economy is estimated to be greater than $2 billion.

Up to 25% of patients who experience acute pancreatitis will suffer a recurrence within several years of the initial event. The recurrence of pancreatitis is a recognized risk factor for pancreatic cancer.

Where You Harmed by Viibryd? Contact an Attorney Today.

Individuals who were diagnosed with acute pancreatitis or pancreatic cancer allegedly linked to Viibryd may be entitled to compensation for medical bills, lost wages and other damages related to their illness. To learn more about filing a Viibryd lawsuit for acute pancreatitis or pancreatic cancer, please contact Bernstein Liebhard LLP today by calling (888) 994-5118.

  1. FDA (2016) “Viibryd Medication Guide”
  2. FDA (2016) “Supplement Approval”
  3. National Pancreas Foundation (2014) “About Acute Pancreatitis”
Last Modified: November 3, 2016

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content